I fully expect, and I will not try to stop a biosimilar IV version of KEYTRUDA coming on to the marketplace.
Ben Ray Luján: “I fully expect, and I will not try to stop a biosimilar IV version of KEYTRUDA coming on to the marketplace.”
Editor's note · Context
Lujan expresses expectation for biosimilar market entry post-patent expiration.
Share
More from Ben Ray Luján
I'm proud to see this legislation advance out of the Indian Affairs Committee, a vital step toward getting this bill across the finish line.
I’ve secured funding for IAIA’s academic programs, fought back against dangerous budget cuts from the Trump administration, and I’ll continue to be a strong advocate for this institution.
If ICE proceeds with purchasing $20 million worth of electric-shock gloves, Congress needs a clear understanding of the device’s safety and authorized uses.
This continuing resolution averts another Republican government shutdown, provides stability for families and communities, and gives Congress time to negotiate bipartisan funding bills.





